Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 4/20 | 0.44 |
| ▸ | P2RX7 | Q99572 | 3/20 | 0.43 |
| ▸ | CAPN1 | P07384 | 2/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | ITGB1 | P05556 | 2/20 | 0.41 |
| ▸ | ITGA4 | P13612 | 2/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21176390 | 0.96 | SIGMAR1 (0.42) | SIGMAR1P2RX7CAPN1POLBL3MBTL1 | |
| SCHEMBL21176162 | 0.87 | CYP2C19 (0.45) | SIGMAR1P2RX7CAPN1ITGB1ITGA4 | |
| SCHEMBL21183582 | 0.87 | P2RX7 (0.51) | SIGMAR1P2RX7CAPN1ITGB1ITGA4 | |
| SCHEMBL21183578 | 0.87 | P2RX7 (0.51) | SIGMAR1P2RX7CAPN1ITGB1ITGA4 | |
| SCHEMBL21176273 | 0.87 | P2RX7 (0.43) | P2RX7CAPN1ITGB1ITGA4GAA | |
| SCHEMBL21183549 | 0.85 | EPHX2 (0.50) | P2RX7CAPN1L3MBTL1GAAALDH1A1 | |
| SCHEMBL19974981 | 0.85 | P2RX7 (0.49) | SIGMAR1P2RX7CAPN1ITGB1ITGA4 | |
| SCHEMBL21183583 | 0.84 | P2RX7 (0.47) | SIGMAR1P2RX7CAPN1ITGB1ITGA4 | |
| SCHEMBL21183550 | 0.82 | CAPN1 (0.47) | SIGMAR1P2RX7CAPN1ITGB1ITGA4 | |
| SCHEMBL21176161 | 0.82 | DPP7 (0.54) | SIGMAR1P2RX7CAPN1POLBL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220356148-A1 | ANTIVIRAL COMPOUNDS | HAPLOGEN GMBH (AT) | 2022-11-10 | — | — | US | disclosed |
| US-11091428-B2 | Antiviral compounds | HAPLOGEN GMBH (AT) | 2021-08-17 | — | — | US | disclosed |
| US-11091428-B2 | Antiviral compounds | HAPLOGEN GMBH (AT) | 2021-08-17 | — | — | US | disclosed |
| US-20190225575-A1 | ANTIVIRAL COMPOUNDS | LUNIS CONSULTING GMBH (AT) | 2019-07-25 | — | — | US | disclosed |
| US-20190225575-A1 | ANTIVIRAL COMPOUNDS | LUNIS CONSULTING GMBH (AT) | 2019-07-25 | — | — | US | disclosed |
| EP-3512836-A1 | ANTIVIRAL COMPOUNDS | Haplogen GmbH (AT) | 2019-07-24 | — | — | EP | disclosed |
| WO-2018050631-A1 | ANTIVIRAL COMPOUNDS | HAPLOGEN GMBH (AT) | 2018-03-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190225575-A1 | ANTIVIRAL COMPOUNDS | PLA2G1B, PLA2G12A, PLA2G4C | SIGMAR1 1966/4885P2RX7 339/4885CAPN1 1497/4885 |
| US-20220356148-A1 | ANTIVIRAL COMPOUNDS | PLA2G12A, PLA2G1B, PLA2G4C | SIGMAR1 2229/4885P2RX7 564/4885CAPN1 1555/4885 |
| US-11091428-B2 | Antiviral compounds | PLA2G1B, PLA2G12A, PLA2G4C | SIGMAR1 1966/4885P2RX7 339/4885CAPN1 1497/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.